A closer look at paroxysmal nocturnal hemoglobinuria | Aplastic Anemia and MDS International Foundation

A closer look at paroxysmal nocturnal hemoglobinuria

Journal Title: 
Eur J Intern Med
Rachidi S, Musallam KM, Taher AT.
Primary Author: 
Rachidi S
Original Publication Date: 
Friday, May 13, 2011

Knowledge of the molecular mechanisms leading to the paroxysmal nocturnal hemoglobinuria (PNH) phenotypes has substantially increased in the past two decades. The associated intravascular hemolysis, hypercoagulablilty, and bone marrow failure result in a wide range of clinical sequlae. Although treatment has usually been symptomatic through several modalities and rarely curative through hematopoietic cell transplantation, recent development of the novel targeted therapeutic agent eculizumab has offered new promises for this highly morbid and fatal disease. This review summarizes current knowledge of the pathophysiology, diagnostic modalities, clinical implications, and treatment approaches of patients with PNH.